EPS

DHT Holdings sells two older tankers for $101.6M, securing a major cash injection. The move highlights a strategy of fleet renewal and shareholder value.

Everybody Loves Languages' CEO and CFO are taking the company private, raising questions about minority shareholder value and the firm's future strategy.

American Express has locked in its 2026 earnings call schedule. Here’s what investors and analysts will be watching for amid shifting economic signals.

Medical cannabis firm Crucial Innovations retains FOCUS Capital Partners, signaling a push for institutional investment and a potential 2026 US listing.

Pharma giant GSK partners with biotech CAMP4, leveraging novel RNA-boosting tech to develop new therapies for neurodegenerative and kidney diseases.

IGM Financial has nearly doubled its share buyback authorization, a bold move signaling deep confidence. What does this mean for investors and the industry?

SCALE AI's record funding fuels 44 new projects, aiming to accelerate homegrown AI and secure Canada's digital future amid fierce global competition.

Pfizer projects lower 2026 earnings as COVID sales wane and patents expire, shifting focus to a multi-billion dollar R&D push for future growth.

A modest dividend payout belies a massive ambition. Canterbury Park is betting its future not on the track, but on building an entire community around it.

As logistics giant Ryder plans a seamless CEO shift from Sanchez to insider John Diez, we analyze the strategy of continuity in a volatile market.

R Systems' acquisition of Novigo is more than a merger; it's a strategic play to fuse AI and automation, creating a powerhouse for autonomous enterprise.

Genmab's $8 billion acquisition of Merus isn't just a deal; it's a bold strategy to own its destiny and dominate the future of oncology therapeutics.

Lument Finance Trust's latest dividend boasts an attractive yield, but recent adjustments raise questions about the health of commercial real estate.

A routine filing reveals a major strategic play. See how BridgeBio Oncology uses special equity grants to attract top minds in the fierce race for a cancer cure.

Argan's repeated dividend hikes and record backlog reflect deep confidence, positioning it to capitalize on surging demand for critical energy infrastructure.

As TD SYNNEX prepares its full-year report, the results will be a crucial test of its AI strategy and a key indicator for the entire IT ecosystem.

Canadian grocer Empire posts strong sales but lower earnings. A deep dive into its dual strategy of store renewal and a major digital and data overhaul.

BW LPG declared a solid dividend, yet its stock fell. We dissect the numbers, peer strategies, and market forces to see what this reveals about the shipping giant.

The industrial giant secured a rare dual 'A' rating from CDP. We decode what this means for its strategy, competitors, and ESG-focused investors.

SBM Offshore’s €141M share buyback is more than routine. It’s a strategic move to boost EPS, signal confidence, and fund its energy transition goals.